Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Does ivermectin have a place in the treatment of mild Covid-19?

Schwartz, E., New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989
May 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19ivm.org
Discussion of ivermectin research compared to paxlovid and molnupiravir. Author includes a meta analysis of low-risk-of-bias studies showing significantly lower hospitalization for outpatient treatment with ivermectin. This efficacy is seen even though treatment was relatively late on average, and even though the Together Trial has been included.
The Together Trial highlights the limitations of risk-of-bias analysis as opposed to more detailed analysis of actual bias. While the Together Trial may theoretically have a low risk of bias at a superficial level when ignoring the conflicts of interest, in practice the bias is very large due to known impossible data, blinding failure, randomization failure, and many protocol failures, in addition to extremely large conflicts of interest1.
Update:2
Reviews covering ivermectin for COVID-19 include3-47.
Schwartz et al., 27 May 2022, peer-reviewed, 1 author. Contact: elischwa@tauex.tau.ac.il.
This PaperIvermectinAll
The new face of monkeypox virus: an emerging global emergency
Nityanand Jain, Edouard Lansiaux, Raimonds Simanis
New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez, None
Biber, Mandelboim, Harmelin, Ram, Shaham, Favorable outcome on viral load and culture viability using Ivermectin in early treatment of nonhospitalized patients with mild COVID-19 -A double-blind, randomized placebo-controlled trial, medRxiv
Bray, Rayner, Noel, Jans, Wagstaff, Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res
Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antiviral Res
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med
Hill, Mirchandani, Pilkington, Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud, Open Forum Infect Dis
Lopez-Medina, Lopez, Hurtado, Davalos, Ramirez et al., Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA
Reis, Silva, Silva, Thabane, Milagres et al., Effect of Early Treatment with Ivermectin among Patients with Covid-19, N Engl J Med
Reyes, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Santin, Scheim, Mccullough, Yagisawa, Borody, Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes New Infect
Vallejos, Zoni, Bangher, Villamandos, Bobadilla et al., Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial, BMC Infect Dis
Zaidi, Dehgani-Mobaraki, The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review, J Antibiot
{ 'indexed': {'date-parts': [[2022, 5, 27]], 'date-time': '2022-05-27T03:41:26Z', 'timestamp': 1653622886130}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 5, 1]], 'date-time': '2022-05-01T00:00:00Z', 'timestamp': 1651363200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 5, 23]], 'date-time': '2022-05-23T00:00:00Z', 'timestamp': 1653264000000}, 'content-version': 'vor', 'delay-in-days': 22, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 5]]}, 'DOI': '10.1016/j.nmni.2022.100989', 'type': 'journal-article', 'created': {'date-parts': [[2022, 5, 27]], 'date-time': '2022-05-27T03:24:37Z', 'timestamp': 1653621877000}, 'page': '100989', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Does ivermectin have a place in the treatment of mild Covid-19?', 'prefix': '10.1016', 'author': [{'given': 'Eli', 'family': 'Schwartz', 'sequence': 'first', 'affiliation': []}], 'member': '78', 'container-title': 'New Microbes and New Infections', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2052297522000415?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2052297522000415?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 5, 27]], 'date-time': '2022-05-27T03:24:38Z', 'timestamp': 1653621878000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2052297522000415'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 5]]}, 'references-count': 0, 'alternative-id': ['S2052297522000415'], 'URL': 'http://dx.doi.org/10.1016/j.nmni.2022.100989', 'relation': {}, 'ISSN': ['2052-2975'], 'subject': ['Infectious Diseases', 'Microbiology'], 'container-title-short': 'New Microbes and New Infections', 'published': {'date-parts': [[2022, 5]]}, 'article-number': '100989'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit